

# Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2019

<https://marketpublishers.com/r/C5D1946E83BEN.html>

Date: June 2019

Pages: 63

Price: US\$ 3,500.00 (Single User License)

ID: C5D1946E83BEN

## Abstracts

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2019

### SUMMARY

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e is a human gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. It promotes tumor development through its role as a cell adhesion molecule. It regulates differentiation, apoptosis, and cell polarity.

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 2 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Adenocarcinoma, Bladder Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pancreatic Cancer, Peritoneal Tumor,

Recurrent Glioblastoma Multiforme (GBM) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and

collaboration details & other developmental activities

The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects

The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Overview

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Companies Involved in Therapeutics Development

Akshaya Bio Inc

Bavarian Nordic A/S

Etubics Corp

OSE Immunotherapeutics

Vaxon Biotech

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Drug Profiles

CV-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-6207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Target CD66e for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-2101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CEA for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CEA for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Dormant Products

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Discontinued Products

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Product Development Milestones

## Featured News & Press Releases

May 22, 2019: OSE Immunotherapeutics to host key opinion leader meeting on novel treatments in non-small cell lung cancer

Apr 02, 2019: OSE Immunotherapeutics Presented new clinical data on Tedopi (OSE2101) at AACR 2019

Feb 28, 2019: OSE Immunotherapeutics to present new clinical data on its immuno-oncology portfolio Tedopi at AACR 2019

Jan 15, 2019: OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi to treat brain metastasis

Nov 21, 2018: OSE receives approval for Phase II trial of tedopi and opdivo

Nov 02, 2018: Bavarian Nordic announces initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers

Oct 10, 2018: Ose Immunotherapeutics and oncology physician network Gercor announce submission of investigational new drug application to evaluate Tedopi in combination with Nivolumab in pancreatic cancer

Sep 20, 2018: Bavarian doses first patient in CV301 and atezolizumab Phase II trial

Aug 10, 2018: HCRN study explores investigational vaccine therapy for metastatic colorectal cancer

Jul 11, 2018: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

Jul 05, 2018: OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi

Jul 02, 2018: OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi

Jun 19, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer

Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Mar 08, 2018: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2019  
Number of Products under Development by Therapy Areas, H1 2019  
Number of Products under Development by Indication, H1 2019  
Number of Products under Development by Companies, H1 2019  
Products under Development by Companies, H1 2019  
Products under Development by Companies, H1 2019 (Contd..1), H1 2019  
Number of Products under Investigation by Universities/Institutes, H1 2019  
Products under Investigation by Universities/Institutes, H1 2019  
Number of Products by Stage and Mechanism of Actions, H1 2019  
Number of Products by Stage and Route of Administration, H1 2019  
Number of Products by Stage and Molecule Type, H1 2019  
Pipeline by Akshaya Bio Inc, H1 2019  
Pipeline by Bavarian Nordic A/S, H1 2019  
Pipeline by Etubics Corp, H1 2019  
Pipeline by OSE Immunotherapeutics, H1 2019  
Pipeline by Vaxon Biotech, H1 2019  
Dormant Products, H1 2019  
Dormant Products, H1 2019 (Contd..1), H1 2019  
Discontinued Products, H1 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2019  
Number of Products under Development by Top 10 Indications, H1 2019  
Number of Products by Stage and Mechanism of Actions, H1 2019  
Number of Products by Routes of Administration, H1 2019  
Number of Products by Stage and Top 10 Routes of Administration, H1 2019  
Number of Products by Molecule Types, H1 2019  
Number of Products by Stage and Molecule Types, H1 2019

### COMPANIES MENTIONED

Akshaya Bio Inc  
Bavarian Nordic A/S  
Etubics Corp  
OSE Immunotherapeutics  
Vaxon Biotech

## I would like to order

Product name: Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H1 2019

Product link: <https://marketpublishers.com/r/C5D1946E83BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5D1946E83BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970